Gut Microbiota as a Drug Discovery Target: Mechanistic Insights and Therapeutic Potential

Trillions of bacteria constitute the gut microbiome of humans and are crucial for maintaining health and controlling the progression of disease. In this report, the complex interplay among gut microbiota and human physiology is discussed in detail with emphasis on its roles in immunological control, metabolism, disease causation, and therapeutic applications. Vitamin synthesis, xenobiotic degradation, maintenance of barrier integrity, and absorption of nutrients are significant microbial activities. Many diseases, such as obesity, diabetes, cardiovascular disease, cancer, inflammatory bowel disease, and neuropsychiatric disorders, are associated with dysbiosis, or a lack of balance in the composition of the microbiota. The work touches on how environmental exposures, antibiotics, and diet influence gut microbiota and shows that early childhood is a critical period for the development of the microbiome. The potential of therapeutic interventions like fecal microbiota transplantation (FMT), probiotics, prebiotics, and genetically engineered bacteria to control disease and re-establish eubiosis is discussed. In addition, the role of personalized medicine is emphasized by the influence of the gut microbiota on drug metabolism and treatment outcomes. Standardization of treatment regimens and further mechanistic insight are required for the translation of microbiome science to clinical practice. Overall, this review summarizes current research and proposes potential directions for the utilization of the gut microbiota to enhance human health.